RegulatoryApr 21, 2026, 07:02 AM
KALA BIO celebrates US Executive Order boosting psychedelic therapy
AI Summary
KALA BIO, Inc. celebrated a landmark Executive Order signed by U.S. President Donald J. Trump on April 18, 2026, which significantly shifts federal psychedelic policy. The order directs the FDA to prioritize psychedelic compound review, reduces DEA research restrictions, expands patient access, and allocates $50 million for research. KALA is strategically positioned to capitalize on this shift, particularly through its Researgency.ai platform, which supports clients like Red Light Holland Corp., strengthening their regulatory and commercial momentum.
Key Highlights
- US President Trump signed an Executive Order on April 18, 2026.
- Order allocates $50 million in federal funding for psychedelic therapy research.
- FDA to prioritize psychedelic compound review; DEA to reduce research restrictions.
- KALA's Researgency.ai platform supports clients like Red Light Holland Corp.
- KALA CEO Avi Minkowitz sees this as a move to mainstream healthcare.